GUTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fractyl Health Inc (GUTS) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak financial performance, neutral trading sentiment, and lacks positive catalysts. Analysts have recently downgraded the stock and reduced price targets significantly. While technical indicators are neutral, there are no compelling reasons to invest immediately.
The MACD histogram is positive at 0.0576 and expanding, suggesting mild bullish momentum. RSI is neutral at 40.292, indicating no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support is at 0.402, and resistance is at 0.5. Overall, technical indicators are neutral.
NULL identified. No recent news or significant positive developments.
Analysts have downgraded the stock and reduced price targets due to disappointing trial data. Financial performance is weak, with revenue dropping to zero and gross margin at 0%.
In Q3 2025, revenue dropped to 0 (-100% YoY). Net income improved to -$45.6M (+96.79% YoY), and EPS improved to -0.71 (+47.92% YoY). Gross margin also dropped to 0%. Overall, financial performance is weak, with no revenue and significant losses.
Analysts have downgraded the stock recently. Morgan Stanley downgraded it to Equal Weight from Overweight and reduced the price target to $2 from $8, citing disappointing trial results. BofA also lowered the price target to $2 from $5 but maintained a Buy rating, citing potential improvements in future trials.
